ClinicalTrials.gg
Enrolling by invitationNCT01803906Updated Jan 7, 2026

Tissue Sample Study for Mitochondrial Disorders

An observational study in Mitochondrial Disorders, Mitochondrial Disease and Melas, sponsored by Columbia University. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Columbia University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
6,900
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Mitochondrial Diseases with a site in United States — 20 open to participants now, 22 under way, 3 of them phase 3. Mitochondrial Diseases · United States.

Planned enrollment
2nd of 31
6,900 · median 61
Started
2012
with 6 others
Observational
31 of 83
10 open now
Primary completion
2026-12
later than 1 of 21 live
Registered
19th of 83
by date
Lead sponsor
6 of 83
Columbia University

Among the 83 studies in Mitochondrial Diseases with a site in United States, this one is the 2nd largest by planned enrollment of the 31 observational ones that give a count, is one of 7 that started in 2012, is one of 31 observational ones, reaches primary completion later than 1 of the 21 other live ones, and was the 19th registered.

Mitochondrial Diseases

189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.

Browse Mitochondrial Diseases studies →

Open to participants now

20 of the 83 studies in Mitochondrial Diseases with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Mitochondrial Diseases with a site in United States, or all of them as a file.
02

Study summary

The investigators are studying patients with undefined mitochondrial diseases to identify genetic mutations in nuclear or mitochondrial Deoxyribonucleic Acid (DNA). Most patients with suspected or known mitochondrial diseases have no genetic confirmation. The investigators expect that evaluating tissue samples from patients with mitochondrial disorders will lead us to discover mutations in new or known genes causing mitochondrial dysfunction.

Read the detailed description

Presently, the investigators know of about 200 mitochondrial disorders. The investigators know that there are about 1,300 genes responsible for mitochondrial function. Thus, there are a lot of mutated genes to be discovered out there. Currently, most patients with suspected or known mitochondrial disorders do not have genetic confirmation of the disease.

The goal of this project is to perform biochemical and DNA analysis on tissue samples of patients with mitochondrial disorders to find new genes that might be involved in mitochondrial dysfunction.

Leftover patient tissue samples will be obtained for analysis from within the Columbia Presbyterian Medical Center. Left over patient samples may also be sent from outside the institution. This is not a "first-step" in the diagnostic process, but rather an option for evaluation in patient samples for which no known diagnosis or genetic confirmation has been made.

The research laboratory does not guarantee that a sample will be analyzed. Sample analysis is performed according to research interest. If they choose, patients can be contacted should laboratory findings provide insight into their disease.

03

Conditions studied

  • Mitochondrial Disorders
  • Mitochondrial Disease
  • Melas
  • Kearns Sayer
  • NARP
  • MNGIE
  • LHON
  • Mitochondrial Depletion Syndrome
  • Leigh's Disease

Keywords

  • mitochondrial disorder
  • mitochondria
  • oxidative phosphorylation
  • oxidative phosphorylation disorders
  • respiratory chain disorders
  • mitochondrial disease
  • melas
  • kearns sayer
  • NARP
  • MNGIE
  • LHON
  • Mitochondrial depletion syndrome
  • Leigh's disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients of all ages, race, gender with known or suspected mitochondrial disorders and their carrier relatives (if requested).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients suspected of having a mitochondrial disorder
  • Patients who may carry a genetic mutation or be related to someone with a genetic mutation which may cause a mitochondrial disorder

Exclusion criteria

Exclusion Criteria:

  • Patients who are not suspected of having a mitochondrial disorder
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
6,900 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Mitochondrial disease

    Patients with known or suspected DNA mutations that affect mitochondrial function. Patients with suspected mitochondrial disorders

06

What researchers measure

Primary outcomes

  1. Number of patients with reduced respiratory chain enzyme levels

    Biochemical studies involving mitochondrial function. The levels will be compared to normal levels.

    Time frame: Up to 2 years

Secondary outcomes

  1. Number of new genetic mutations

    Evaluation of potential genetic interaction in clinical signs and symptoms.

    Time frame: Up to 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — When applicable we will submit manuscript (s) describing the findings

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2012 (actual). Primary completion is estimated for Dec 2026, 178 months after the start.

Of 33 observational studies under Mitochondrial Diseases, half reached primary completion within 169 months of starting (the median), counting those still running; a quarter within 26. This study's planned 178 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2012
First posted
Mar 4, 2013
StartActual
Feb 2012
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01803906
Responsible party
Sponsor
First posted
Mar 4, 2013
Start date
Feb 2012
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 7, 2026

Study contacts

Michio Hirano, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion